



	<b>Dr. Vinay Chopra</b> MD (Pathology & Micr Chairman & Consultar	obiology)		(Pathology)	
NAME	: Mrs. RAJNI				
AGE/ GENDER	: 30 YRS/FEMALE		PATIENT ID	: 1687604	
COLLECTED BY	:		<b>REG. NO./LAB NO.</b>	:012412	010037
<b>REFERRED BY</b>	:		<b>REGISTRATION DATE</b>		2024 12:37 PM
BARCODE NO.	: 01521805		COLLECTION DATE		2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	:01/Dec/2	2024 01:06PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMB/	ALA CANTI			
Test Name		Value	Unit	I	Biological Reference interval
	SWAST	HVA WE	ELLNESS PANEL: GT	-	
			OOD COUNT (CBC)		
PED BLOOD CELLS	(RBCS) COUNT AND INDICES	LEIEDL			
HAEMOGLOBIN (HE		12.8	gm/dL		12.0 - 16.0
by CALORIMETRIC			Ū.		
RED BLOOD CELL (F	RBC) COUNT	4.7	Millions/	cmm 3	3.50 - 5.00
PACKED CELL VOLU	ME (PCV) JTOMATED HEMATOLOGY ANALYZER	39.8	%	:	37.0 - 50.0
MEAN CORPUSCULA		84.8	fL	8	80.0 - 100.0
MEAN CORPUSCULA	AR HAEMOGLOBIN (MCH) JTOMATED HEMATOLOGY ANALYZER	27.2	pg		27.0 - 34.0
MEAN CORPUSCULA	AR HEMOGLOBIN CONC. (MCHC) JTOMATED HEMATOLOGY ANALYZER	32	g/dL	:	32.0 - 36.0
RED CELL DISTRIBU	JTION WIDTH (RDW-CV) JTOMATED HEMATOLOGY ANALYZER	13.1	%		11.00 - 16.00
	JTION WIDTH (RDW-SD) JTOMATED HEMATOLOGY ANALYZER	41.7	fL	:	35.0 - 56.0
MENTZERS INDEX by CALCULATED		18.04	RATIO	]	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING IND by CALCULATED WHITE BLOOD CEL		23.61	RATIO	(	BETA THALASSEMIA TRAIT:<= 65.0 IRON DEFICIENCY ANEMIA: > 65.0
TOTAL LEUCOCYTE		7640	/cmm		4000 - 11000
by FLOW CYTOMETRY	BY SF CUBE & MICROSCOPY				
	LOOD CELLS (nRBCS) T HEMATOLOGY ANALYZER	NIL		(	0.00 - 20.00
	LOOD CELLS (nRBCS) % itomated hematology analyzer	NIL	%	•	< 10 %





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com
 www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





Dr. Vinay Chopra

MD (Pathology & Microbiology) Chairman & Consultant Pathologist



Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME	: Mrs. RAJNI		
AGE/ GENDER	: 30 YRS/FEMALE	PATIENT ID	: 1687604
COLLECTED BY	:	REG. NO./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	<b>COLLECTION DATE</b>	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	<b>REPORTING DATE</b>	:01/Dec/2024 01:06PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTI		

Test Name	Value	Unit	<b>Biological Reference interval</b>
DIFFERENTIAL LEUCOCYTE COUNT (DLC)			
NEUTROPHILS by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	66	%	50 - 70
LYMPHOCYTES by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	27	%	20 - 40
EOSINOPHILS by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	1	%	1 - 6
MONOCYTES by flow cytometry by sf cube & microscopy	6	%	2 - 12
BASOPHILS by flow cytometry by sf cube & microscopy ABSOLUTE LEUKOCYTES (WBC) COUNT	0	%	0 - 1
ABSOLUTE NEUTROPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	5042	/cmm	2000 - 7500
ABSOLUTE LYMPHOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	2063	/cmm	800 - 4900
ABSOLUTE EOSINOPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	76	/cmm	40 - 440
ABSOLUTE MONOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	458	/cmm	80 - 880
ABSOLUTE BASOPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	/cmm	0 - 110
ABSOLUTE IMMATURE GRANULOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	/cmm	0.0 - 999.0
PLATELETS AND OTHER PLATELET PREDICTIVE	MARKERS.		
PLATELET COUNT (PLT) by hydro dynamic focusing, electrical impedence	217000	/cmm	150000 - 450000
PLATELETCRIT (PCT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	0.27	%	0.10 - 0.36
MEAN PLATELET VOLUME (MPV) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	12 <sup>H</sup>	fL	6.50 - 12.0
PLATELET LARGE CELL COUNT (P-LCC) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	90000	/cmm	30000 - 90000
PLATELET LARGE CELL RATIO (P-LCR) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	41.6	%	11.0 - 45.0
PLATELET DISTRIBUTION WIDTH (PDW) by hydro dynamic focusing, electrical impedence	16.4	%	15.0 - 17.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com







	<b>Dr. Vinay Chopra</b> MD (Pathology & Microbiolo Chairman & Consultant Path		(Pathology)
NAME	: Mrs. RAJNI		
AGE/ GENDER	: 30 YRS/FEMALE	PATIENT ID	: 1687604
COLLECTED BY	:	<b>REG. NO./LAB NO.</b>	: 012412010037
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	<b>COLLECTION DATE</b>	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	<b>REPORTING DATE</b>	: 01/Dec/2024 01:06PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CA	ANTT	
Test Name	Valu	e Unit	Biological Reference interval

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com







	Dr. Vinay Cho MD (Pathology & Chairman & Cons	Microbiology)		(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE		PATIENT ID	: 1687604
COLLECTED BY	:		REG. NO./LAB NO.	: 012412010037
REFERRED BY	<u>.</u>		REGISTRATION DATE	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805		COLLECTION DATE	: 01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 03/Dec/2024 01:14PM
CLIENT CODE.	: 6349/1, NICHOLSON ROAD, A		KEI ONTENU DATE	. 03/ Dec/ 2024 01.141 W
CLIENT ADDRESS	. 0349/ I, MICHOLSON KOAD, F	AWIDALA CAN I I		
Test Name		Value	Unit	Biological Reference interva
			20	40-64
WHOLE BLOOD by hplc (high perfo ESTIMATED AVERA	AEMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) AGE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY)	5 96.8	% mg/dL	4.0 - 6.4 60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERA by HPLC (HIGH PERFO	RMANCE LIQUID CHROMATOGRAPHY) AGE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY)	96.8	mg/dL	
WHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERA by HPLC (HIGH PERFO INTERPRETATION:	RMANCE LIQUID CHROMATOGRAPHY) AGE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN	96.8 DIABETES ASSOCI	mg/dL ATION (ADA):	60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERA by HPLC (HIGH PERFO INTERPRETATION:	RMANCE LIQUID CHROMATOGRAPHY) AGE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN REFERENCE GROUP	96.8 DIABETES ASSOCI	mg/dL	60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERA by HPLC (HIGH PERFO INTERPRETATION: Non di	RMANCE LIQUID CHROMATOGRAPHY) AGE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN	96.8 DIABETES ASSOCI	mg/dL ATION (ADA): YCOSYLATED HEMOGLOGIB	60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERA by HPLC (HIGH PERFO INTERPRETATION: NON di A	RMANCE LIQUID CHROMATOGRAPHY) AGE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN REFERENCE GROUP abetic Adults >= 18 years	96.8 DIABETES ASSOCI	mg/dL ATION (ADA): YCOSYLATED HEMOGLOGIB <5.7 5.7 - 6.4 >= 6.5	60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERA by HPLC (HIGH PERFO INTERPRETATION: NON di A	RMANCE LIQUID CHROMATOGRAPHY) AGE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN REFERENCE GROUP abetic Adults >= 18 years tt Risk (Prediabetes)	96.8 DIABETES ASSOCI	mg/dL ATION (ADA): YCOSYLATED HEMOGLOGIB <5.7 5.7 - 6.4 >= 6.5 Age > 19 Years	60.00 - 140.00 (HBAIC) in %
WHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERA by HPLC (HIGH PERFO INTERPRETATION: Non di A D	RMANCE LIQUID CHROMATOGRAPHY) AGE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN REFERENCE GROUP abetic Adults >= 18 years tt Risk (Prediabetes) Diagnosing Diabetes	96.8 DIABETES ASSOCI GL GOals	mg/dL ATION (ADA): YCOSYLATED HEMOGLOGIB <5.7 5.7 - 6.4 >= 6.5 Age > 19 Years of Therapy:	60.00 - 140.00 (HBAIC) in %
WHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERA by HPLC (HIGH PERFO INTERPRETATION: Non di A D	RMANCE LIQUID CHROMATOGRAPHY) AGE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN REFERENCE GROUP abetic Adults >= 18 years tt Risk (Prediabetes)	96.8 DIABETES ASSOCI GL GOals	mg/dL ATION (ADA): YCOSYLATED HEMOGLOGIB <5.7 5.7 - 6.4 >= 6.5 Age > 19 Years	60.00 - 140.00 (HBAIC) in %

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients. 2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.

4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT





	Dr. Vinay Cho MD (Pathology & Chairman & Cons	Microbiology)	Dr. Yugam ( MD (P CEO & Consultant Pa	athology)
AME	: Mrs. RAJNI			
GE/ GENDER	: 30 YRS/FEMALE	PATI	ENT ID	: 1687604
OLLECTED BY	:	REG. I	NO./LAB NO.	: 012412010037
EFERRED BY	:	REGIS	TRATION DATE	: 01/Dec/2024 12:37 PM
ARCODE NO.	: 01521805	COLLI	ECTION DATE	:01/Dec/2024 12:48PM
LIENT CODE.	: KOS DIAGNOSTIC LAB	REPO	RTING DATE	:01/Dec/2024 01:20PM
LIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	MBALA CANTT		
'est Name		Value	Unit	Biological Reference interval
ystemic lupus eryth ONDITION WITH LO	ematosus			ve diseases as well as some others, such as

KOS Diagnostic Lab (A Unit of KOS Healthcare)





**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







Dr. Vinay C MD (Pathology Chairman & Co				(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE	PAT	IENT ID	: 1687604
COLLECTED BY	:	REG	. NO./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:		ISTRATION DATE	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805		LECTION DATE	:01/Dec/2024 12:48PM
CLIENT CODE. CLIENT ADDRESS	: KOS DIAGNOSTIC LAB : 6349/1, NICHOLSON ROAD, AMI		ORTING DATE	: 02/Dec/2024 06:05PM
			Tinit	Piological Deference interval
Test Name		Value	Unit	Biological Reference interval
HAEMOGLOBIN VA		84.5	QUID CHROMAI %	83.00 - 90.00
HAEMOGLOBIN F ()		<0.8	%	0.00 - 2.0
HAEMOGLOBIN A2	RMANCE LIQUID CHROMATOGRAPHY)	3.6	%	1.50 - 3.70
PEAK 3		4.9	%	< 10.0
OTHERS-NON SPEC	RMANCE LIQUID CHROMATOGRAPHY) CIFIC RMANCE LIQUID CHROMATOGRAPHY)	ABSENT	%	ABSENT
HAEMOGLOBIN S by HPLC (HIGH PERFO	RMANCE LIQUID CHROMATOGRAPHY)	NOT DETECTE	ED %	< 0.02
HAEMOGLOBIN D (	PUNJAB) rmance liquid chromatography)	NOT DETECTE	ED %	< 0.02
HAEMOGLOBIN E by HPLC (HIGH PERFO	RMANCE LIQUID CHROMATOGRAPHY)	NOT DETECTE	ED %	< 0.02
HAEMOGLOBIN C by HPLC (HIGH PERFO	RMANCE LIQUID CHROMATOGRAPHY)	NOT DETECTE	ED %	< 0.02
UNKNOWN UNIDEN by HPLC (HIGH PERFO	NTIFIED VARIANTS RMANCE LIQUID CHROMATOGRAPHY)	NOT DETECTE	ED %	< 0.02
WHOLE BLOOD by HPLC (HIGH PERFO	XEMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) (RBCS) COUNT AND INDICES	5	%	4.0 - 6.4
HAEMOGLOBIN (HI	B)	12.8	gm/dL	12.0 - 16.0
RED BLOOD CELL (I by AUTOMATED HEMA	RBC) COUNT	4.7	Millions/	′cmm 3.50 - 5.00
PACKED CELL VOLU	JME (PCV)	39.8	%	37.0 - 50.0
MEAN CORPUSCULA	AR VOLUME (MCV)	84.8	fL	80.0 - 100.0
MEAN CORPUSCUL	AR HAEMOGLOBIN (MCH) Itology analyzer	27.2	pg	27.0 - 34.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

Page 6 of 26





	Dr. Vinay Chopr MD (Pathology & Mic Chairman & Consulta	robiology)	Dr. Yugam MD CEO & Consultant	(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE	PA	ATIENT ID	: 1687604
COLLECTED BY	:	RI	EG. NO./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:	RI	EGISTRATION DATE	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	CO	<b>DLLECTION DATE</b>	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	RI	EPORTING DATE	: 02/Dec/2024 06:05PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMB	BALA CANTT		
Test Name		Value	Unit	Biological Reference interval
MEAN CORPUSCUL by AUTOMATED HEMA	AR HEMOGLOBIN CONC. (MCHC)	32	g/dL	32.0 - 36.0
RED CELL DISTRIB	UTION WIDTH (RDW-CV) ATOLOGY ANALYZER	13.1	%	11.00 - 16.00
RED CELL DISTRIB	UTION WIDTH (RDW-SD) ATOLOGY ANALYZER	41.7	fL	35.0 - 56.0

by AUTOMATED HEMATOLOGY ANALYZER OTHERS			
NAKED EYE SINGLE TUBE RED CELL OSMOTIC FRAGILITY TEST by single red cell osmotic fragility	NEGATIVE (-ve)		NEGATIVE (-ve)
MENTZERS INDEX by CALCULATED	18.04	RATIO	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA:

>13.0

# **INTERPRETATION**

# THE ABOVE FINDINGS ARE SUGGESTIVE OF NORMAL HAEMOGLOBIN CHROMATOGRAPHIC PATTERN

# **INTERPRETATION:**

The Thalassemia syndromes, considered the most common genetic disorder worldwide, are a heterogenous group of mandelian disorders, all characterized by a lack of/or decreased synthesis of either the alpha-globin chains (alpha thalassemia) or the beta-globin chains (beta thalassemia) of haemoglobin.

# HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC):

1.HAEMOGLOBIN VARIANT ANALYSIS, BLOOD- High Performance liquid chromatography (HPLC) is a fast & accurate method for determining the presence and for quatitation of various types of normal haemoglobin and common abnormal hb variants, including but not limited to Hb S, C, E, D and Beta -thalassemia.

2. The diagnosis of these abnormal haemoglobin should be confirmed by DNA analysis.

3. The method use has a limited role in the diagnosis of alpha thalassemia.

4. Slight elevation in haemoglobin A2 may also occur in hyperthyroidism or when there is deficiency of vitamin b12 or folate and this should be istinguished from inherited elevation of HbA2 in Beta- thalassemia trait.

# NAKED EYE SINGLE TUBE RED CELL OSMOTIC FRAGILITY TEST (NESTROFT):

1.It is a screening test to distinguish beta thalassemia trait. Also called as Naked Eye Single Tube Red Cell Osmotic Fragility Test.

2. The test showed a sensitivity of 100%, specificity of 85.47%, a positive predictive value of 66% and a negative predictive value of 100%. 3.A high negative predictive value can reasonably rule out beta thalassemia trait cases. So, it should be adopted as a screening test for beta thalassemia trait, as it is not practical or feasible to employ HbA2 in every case of anemia in childhood.

# MENTZERS INDEX:

1. The Mentzer index, helpful in differentiating iron deficiency anemia from beta thalassemia. If a CBC indicates microcytic anemia, the Mentzer index is said to be a method of distinguishing between them.

2. If the index is less than 13, thalassemia is said to be more likely. If the result is greater than 13, then iron-deficiency anemia is said to be more likelv

3. The principle involved is as follows: In iron deficiency, the marrow cannot produce as many RBCs and they are small (microcytic), so the RBC





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com





	Dr. Vinay Chc MD (Pathology & Chairman & Consi	Microbiology)	gam Chopra MD (Pathology) tant Pathologist
NAME	: Mrs. RAJNI		
AGE/ GENDER	: 30 YRS/FEMALE	PATIENT ID	: 1687604
COLLECTED BY	:	<b>REG. NO./LAB NO.</b>	: 012412010037
<b>REFERRED BY</b>	:	<b>REGISTRATION DAT</b>	E : 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	COLLECTION DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	<b>REPORTING DATE</b>	: 02/Dec/2024 06:05PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	MBALA CANTT	
Test Name		Value Unit	Biological Reference interval

count and the MCV will both be low, and as a result, the index will be greater than 13. Conversely, in thalassemia, which is a disorder of globin synthesis, the number of RBC's produced is normal, but the cells are smaller and more fragile. Therefore, the RBC count is normal, but the MCV is low, so the index will be less than 13.

**NOTE:** In practice, the Mentzer index is not a reliable indicator and should not, by itself, be used to differentiate. In addition, it would be possible for a patient with a microcytic anemia to have both iron deficiency and thalassemia, in which case the index would only suggest iron deficiency.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com







	Dr. Vinay Cł MD (Pathology & Chairman & Cor		Dr. Yugam MD CEO & Consultant	(Pathology)
IAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE	PATI	ENT ID	: 1687604
COLLECTED BY	:	REG. I	NO./LAB NO.	: 012412010037
REFERRED BY	:	REGIS	<b>TRATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	:01521805	COLL	ECTION DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPO	RTING DATE	:01/Dec/2024 02:04PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	, AMBALA CANTT		
Test Name		Value	Unit	<b>Biological Reference interval</b>
	CI INI	CAL CHEMISTRY	BIOCHEMIST	RY
	CLINI			
	CLINI	GLUCOSE FAST		

KOS Diagnostic Lab (A Unit of KOS Healthcare)

A fasting plasma glucose level below 100 mg/dl is considered normal.
 A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood

test (after consumption of 75 gms of glucose) is recommended for all such patients. 3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.





**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



	<b>Dr. Vinay Ch</b> MD (Pathology & Chairman & Con		Dr. Yugam MD CEO & Consultant	(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE	PA	TIENT ID	: 1687604
COLLECTED BY	:	RI	G. NO./LAB NO.	: 012412010037
REFERRED BY	:	RI	GISTRATION DATE	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805		LLECTION DATE	: 01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		PORTING DATE	:01/Dec/2024 02:45PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,			
Test Name		Value	Unit	Biological Reference interval
		LIPID PROF	II F · BASIC	
CHOLESTEROL TO		137.37	mg/dL	OPTIMAL: < 200.0
by CHOLESTEROL OX		157.57	ing/ uL	BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR =
				240.0
FRIGLYCERIDES: S by GLYCEROL PHOSE	ERUM PHATE OXIDASE (ENZYMATIC)	97.23	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0
				VERY HIGH: $> OR = 500.0$
HDL CHOLESTERO	L (DIRECT): SERUM Ion	55.84	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30 60.0
			( 17	HIGH HDL: $> OR = 60.0$
LDL CHOLESTEROI by CALCULATED, SPE		62.08	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLEST by CALCULATED, SPE		81.53	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 15 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTER	DL: SERUM	19.45	mg/dL	0.00 - 45.00
by CALCULATED, SPE FOTAL LIPIDS: SER by CALCULATED, SPE	сткорнотометку 2UM	371.97	mg/dL	350.00 - 700.00
CHOLESTEROL/HD by CALCULATED, SPE	DL RATIO: SERUM	2.46	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0



**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







Dr. Vinay ChopraDr. Yugam ChopraMD (Pathology & Microbiology)MD (Pathology)Chairman & Consultant PathologistCEO & Consultant Pathologist							
NAME	: Mrs. RAJNI						
AGE/ GENDER	: 30 YRS/FEMALE	РАТ	TENT ID	: 1687604			
<b>COLLECTED BY</b>	:	REG	. NO./LAB NO.	: 012412010037			
<b>REFERRED BY</b>	:	REG	ISTRATION DATE	: 01/Dec/2024 12:37 PM			
BARCODE NO.	: 01521805	COL	LECTION DATE	:01/Dec/2024 12:48PM			
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REP	ORTING DATE	:01/Dec/2024 02:45PM			
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT						
Test Name		Value	Unit	<b>Biological Reference interval</b>			
LDL/HDL RATIO: S by CALCULATED, SPE		1.11	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0			
TRIGLYCERIDES/H by CALCULATED, SPE		1.74 <sup>L</sup>	RATIO	3.00 - 5.00			

## INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

 Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
 NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com







MD (Pathology)

:1687604

:012412010037

:01/Dec/2024 12:37 PM

:01/Dec/2024 12:48PM

:01/Dec/2024 02:45PM

Dr. Vinay Chopra Dr. Yugam Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist **CEO & Consultant Pathologist** : Mrs. RAJNI : 30 YRS/FEMALE **PATIENT ID** REG. NO./LAB NO. : **REGISTRATION DATE** : :01521805 **COLLECTION DATE** : KOS DIAGNOSTIC LAB **REPORTING DATE CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	<b>Biological Reference interval</b>
LIVER	FUNCTION T	TEST (COMPLETE)	
BILIRUBIN TOTAL: SERUM by diazotization, spectrophotometry	0.53	mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20
BILIRUBIN DIRECT (CONJUGATED): SERUM by DIAZO MODIFIED, SPECTROPHOTOMETRY	0.15	mg/dL	0.00 - 0.40
BILIRUBIN INDIRECT (UNCONJUGATED): SERUM by CALCULATED, SPECTROPHOTOMETRY	0.38	mg/dL	0.10 - 1.00
SGOT/AST: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	19.2	U/L	7.00 - 45.00
SGPT/ALT: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	17.3	U/L	0.00 - 49.00
AST/ALT RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.11	RATIO	0.00 - 46.00
ALKALINE PHOSPHATASE: SERUM by PARA NITROPHENYL PHOSPHATASE BY AMINO METHYL PROPANOL	80.19	U/L	40.0 - 130.0
GAMMA GLUTAMYL TRANSFERASE (GGT): SERUM by SZASZ, SPECTROPHTOMETRY	16.75	U/L	0.00 - 55.0
TOTAL PROTEINS: SERUM by BIURET, SPECTROPHOTOMETRY	6.86	gm/dL	6.20 - 8.00
ALBUMIN: SERUM by BROMOCRESOL GREEN	4.55	gm/dL	3.50 - 5.50
GLOBULIN: SERUM by CALCULATED, SPECTROPHOTOMETRY	2.31	gm/dL	2.30 - 3.50
A : G RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.97	RATIO	1.00 - 2.00

#### INTERPRETATION

NOTE:- To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range. USE: - Differential diagnosis of diseases of hepatobiliary system and pancreas.

# **INCREASED:**

> 2
> 2 (Highly Suggestive)
1.4 - 2.0
> 1.5
> 1.3 (Slightly Increased)





**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



NAME

AGE/ GENDER

**COLLECTED BY** 

**REFERRED BY** 

**BARCODE NO.** 

CLIENT CODE.





	Dr. Vinay Chopi MD (Pathology & Mio Chairman & Consulta	crobiology) ME	m Chopra D (Pathology) ht Pathologist
NAME	: Mrs. RAJNI		
AGE/ GENDER	: 30 YRS/FEMALE	PATIENT ID	: 1687604
COLLECTED BY	:	REG. NO./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	COLLECTION DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	<b>REPORTING DATE</b>	:01/Dec/2024 02:45PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMI	BALA CANTT	
Test Name		Value Unit	Biological Reference interval

## DECREASED:

1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)

2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com







	Dr. Vinay Cho MD (Pathology & N Chairman & Consu	1icrobiology)	Dr. Yugam ( MD (F CEO & Consultant P	Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE	P	ATIENT ID	: 1687604
COLLECTED BY	:	R	EG. NO./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:	R	EGISTRATION DATE	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	C	OLLECTION DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	R	EPORTING DATE	:01/Dec/2024 02:45PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AI	MBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
	KIDNI	Y FUNCTION	TEST (COMPLETE)	
UREA: SERUM		18.81	mg/dL	10.00 - 50.00
by UREASE - GLUTAM	ATE DEHYDROGENASE (GLDH)		U	
CREATININE: SERU		0.91	mg/dL	0.40 - 1.20
BLOOD UREA NITR	OGEN (BUN): SERUM	8.79	mg/dL	7.0 - 25.0
by CALCULATED, SPE	ECTROPHOTOMETRY ROGEN (BUN)/CREATININE	I a a a	RATIO	10.0 - 20.0
RATIO: SERUM	UGEN (DUN)/ CREATININE	9.66 <sup>L</sup>	KATIO	10.0 - 20.0
by CALCULATED, SPE				
UREA/CREATININ by CALCULATED, SPE		20.67	RATIO	
URIC ACID: SERUM		2.52	mg/dL	2.50 - 6.80
by URICASE - OXIDAS CALCIUM: SERUM	EPEROXIDASE	9.49	mg/dL	8.50 - 10.60
by ARSENAZO III, SPE	CTROPHOTOMETRY	0.10	U	0.00 10.00
PHOSPHOROUS: SE	RUM DATE, SPECTROPHOTOMETRY	2.98	mg/dL	2.30 - 4.70
ELECTROLYTES	ATE, SI LOTION HOTOMETRI			
SODIUM: SERUM		139.3	mmol/L	135.0 - 150.0
by ISE (ION SELECTIV POTASSIUM: SERU		4.21	mmol/L	2.50 5.00
by ISE (ION SELECTIV		4.21	IIIII01/L	3.50 - 5.00
CHLORIDE: SERUM	ſ	104.48	mmol/L	90.0 - 110.0
by ISE (ION SELECTIV ESTIMATED GLOM	'E ELECTRODE) <b>IERULAR FILTERATION RATE</b>			
	ERULAR FILTERATION RATE	87		

# **INTERPRETATION:**

To differentiate between pre- and post renal azotemia.

INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.

2. Catabolic states with increased tissue breakdown.

3. GI haemorrhage.



**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT





		Dr. Vinay Chopra MD (Pathology & Microt Chairman & Consultant			gam Chop MD (Patholog Iltant Patholog	gy)			
IAME	: Mrs. RAJNI								
GE/ GENDER	: 30 YRS/FEN	1AI F	PA	TIENT ID	: 1687	604			
							~		
COLLECTED BY	:			EG. NO./LAB NO.		41201003			
REFERRED BY	:		RI	GISTRATION DAT	<b>FE</b> : 01/I	ec/2024 12	2:37 PM		
BARCODE NO.	:01521805		CC	<b>LLECTION DATE</b>	:01/[	ec/2024 12	2:48PM		
CLIENT CODE.	: KOS DIAGN	OSTIC LAB	RI	EPORTING DATE	:01/I	ec/2024 02	2:45PM		
CLIENT ADDRESS	: 6349/1, NI	CHOLSON ROAD, AMBAL	A CANTT						
Test Name		T	alue	Unit		Biologi	cal Refe	rence in	terval
9. Certain drugs (e.g. <b>NCREASED RATIO (&gt;2</b>	ass (subnorma tetracycline, gl 0:1) WITH ELEV (BUN rises dis superimposed 0:1) WITH DEC osis.	lostomy) I creatinine production) ucocorticoids) <b>/ATED CREATININE LEVELS</b> proportionately more that on renal disease.		(e.g. obstructive u	ropathy).				
<ol> <li>Reduced muscle m</li> <li>Certain drugs (e.g.</li> <li>NCREASED RATIO (&gt;2</li> <li>Postrenal azotemia</li> <li>Prerenal azotemia</li> <li>PCREASED RATIO (&lt;1</li> <li>Acute tubular necr</li> <li>Low protein diet ar</li> <li>Severe liver disease</li> <li>Other causes of de</li> <li>Repeated dialysis (</li> <li>SIADH (syndrome c</li> <li>Pregnancy.</li> <li>PCREASED RATIO (&lt;1</li> <li>Phenacimide thera</li> <li>Rabdomyolysis (r</li> </ol>	(e.g. ureter co ass (subnorma tetracycline, gl <b>0:1) WITH ELEV</b> (BUN rises dis superimposed <b>0:1) WITH DEC</b> osis. d starvation. creased urea s urea rather tha monemias (ure f inappropiate <b>0:1) WITH INCF</b> oy (accelerates eleases muscle	lostomy) I creatinine production) ucocorticoids) ATED CREATININE LEVELS proportionately more that on renal disease. REASED BUN : an creatinine diffuses our as is virtually absent in bl antidiuretic harmone) du REASED CREATININE: a conversion of creatine t creatinine).	an creatinine t of extracelli ood). ue to tubular	ular fluid). secretion of urea.	ropathy).				
<ol> <li>Reduced muscle m</li> <li>Certain drugs (e.g.</li> <li>NCREASED RATIO (&gt;2</li> <li>Postrenal azotemia</li> <li>Prerenal azotemia</li> <li>Prerenal azotemia</li> <li>DECREASED RATIO (&lt;1</li> <li>Acute tubular necr</li> <li>Low protein diet ar</li> <li>Severe liver disease</li> <li>Other causes of de</li> <li>Repeated dialysis (</li> <li>SIADH (syndrome c</li> <li>Pregnancy.</li> <li>DECREASED RATIO (&lt;1</li> <li>Phenacimide thera</li> <li>Rabdomyolysis (r</li> <li>Muscular patients</li> </ol>	(e.g. ureter co ass (subnorma tetracycline, gl <b>0:1) WITH ELEV</b> (BUN rises dis superimposed <b>0:1) WITH DEC</b> osis. d starvation. creased urea so urea rather tha monemias (ure f inappropiate <b>0:1) WITH INCF</b> oy (accelerates eleases muscle who develop re	lostomy) I creatinine production) ucocorticoids) ATED CREATININE LEVELS proportionately more that on renal disease. REASED BUN : an creatinine diffuses our ta is virtually absent in bl antidiuretic harmone) du REASED CREATININE: a conversion of creatine t creatinine). enal failure.	an creatinine t of extracelli ood). ue to tubular o creatinine)	ular fluid). secretion of urea.					
<ol> <li>Reduced muscle m</li> <li>Certain drugs (e.g.</li> <li>NCREASED RATIO (&gt;2</li> <li>Postrenal azotemia</li> <li>Prerenal azotemia</li> <li>Prerenal azotemia</li> <li>DECREASED RATIO (&lt;1</li> <li>Acute tubular necr</li> <li>Low protein diet ar</li> <li>Severe liver disease</li> <li>Other causes of de</li> <li>Repeated dialysis (</li> <li>Inherited hyperam</li> <li>SIADH (syndrome c</li> <li>Pregnancy.</li> <li>PCREASED RATIO (&lt;1</li> <li>Phenacimide thera</li> <li>Rhabdomyolysis (r</li> <li>Muscular patients</li> <li>NAPPROPIATE RATIO</li> </ol>	(e.g. ureter co ass (subnorma tetracycline, gl <b>0:1) WITH ELEV</b> (BUN rises dis superimposed <b>0:1) WITH DEC</b> osis. d starvation. creased urea s urea rather tha monemias (ure f inappropiate <b>0:1) WITH INCF</b> oy (accelerates eleases muscle who develop re sis (acetoaceta	lostomy) I creatinine production) ucocorticoids) ATED CREATININE LEVELS proportionately more that on renal disease. REASED BUN : an creatinine diffuses our as is virtually absent in bl antidiuretic harmone) du REASED CREATININE: a conversion of creatine t creatinine). enal failure. te causes false increase	an creatinine t of extracelli ood). ue to tubular o creatinine)	ular fluid). secretion of urea.		Iting in nor	mal ratio	) when de	hydratic
<ol> <li>Reduced muscle m</li> <li>Certain drugs (e.g.</li> <li>NCREASED RATIO (&gt;2</li> <li>Postrenal azotemia</li> <li>Prerenal azotemia</li> <li>Prerenal azotemia</li> <li>DECREASED RATIO (&lt;1</li> <li>Acute tubular necr</li> <li>Low protein diet ar</li> <li>Severe liver disease</li> <li>Other causes of de</li> <li>Repeated dialysis (</li> <li>Inherited hyperam</li> <li>SIADH (syndrome c</li> <li>Pregnancy.</li> <li>DECREASED RATIO (&lt;1</li> <li>Phenacimide thera</li> <li>Rhabdomyolysis (r</li> <li>Muscular patients</li> <li>NAPPROPIATE RATIO</li> <li>Diabetic ketoacido</li> <li>should produce an in</li> <li>Cephalosporin ther</li> </ol>	(e.g. ureter co ass (subnorma tetracycline, gl <b>0:1) WITH ELEV</b> (BUN rises dis superimposed <b>0:1) WITH DEC</b> osis. d starvation. creased urea sy urea rather tha monemias (urea f inappropiate <b>0:1) WITH INCF</b> oy (accelerates eleases muscle who develop re- sis (acetoaceta creased BUN/c apy (interferes	lostomy) I creatinine production) ucocorticoids) ATED CREATININE LEVELS proportionately more that on renal disease. REASED BUN : an creatinine diffuses our a is virtually absent in bl antidiuretic harmone) du REASED CREATININE: conversion of creatine t creatinine). enal failure. te causes false increase reatinine ratio). with creatinine measure	an creatinine t of extracelli ood). ue to tubular o creatinine) in creatinine	ular fluid). secretion of urea.		Iting in nor	mal ratio	) when de	hydratic
<ol> <li>Reduced muscle m</li> <li>Certain drugs (e.g.</li> <li>NCREASED RATIO (&gt;2</li> <li>Postrenal azotemia</li> <li>Prerenal azotemia</li> <li>DECREASED RATIO (&lt;1</li> <li>Acute tubular necr</li> <li>Low protein diet ar</li> <li>Severe liver disease</li> <li>Other causes of de</li> <li>Repeated dialysis (</li> <li>Inherited hyperam</li> <li>SIADH (syndrome c</li> <li>Pregnancy.</li> <li>DECREASED RATIO (&lt;1</li> <li>Phenacimide thera</li> <li>Rhabdomyolysis (r</li> <li>Muscular patients</li> <li>NAPPROPIATE RATIO</li> <li>Diabetic ketoacido</li> <li>hould produce an in</li> <li>Cephalosporin thera</li> </ol>	(e.g. ureter co ass (subnorma tetracycline, gl <b>0:1) WITH ELEV</b> (BUN rises dis superimposed <b>0:1) WITH DEC</b> osis. d starvation. creased urea sy urea rather tha monemias (urea f inappropiate <b>0:1) WITH INCF</b> oy (accelerates eleases muscle who develop re- sis (acetoaceta creased BUN/c apy (interferes	lostomy) I creatinine production) ucocorticoids) ATED CREATININE LEVELS proportionately more that on renal disease. REASED BUN : an creatinine diffuses our a is virtually absent in bl antidiuretic harmone) du REASED CREATININE: conversion of creatine t creatinine). enal failure. te causes false increase reatinine ratio). with creatinine measure	an creatinine t of extracelli ood). ue to tubular o creatinine) in creatinine ment).	ular fluid). secretion of urea.		-	mal ratio	) when de	hydratic
A. Reduced muscle m Certain drugs (e.g. NCREASED RATIO (>2 Prerenal azotemia DECREASED RATIO (<1 Acute tubular necr Low protein diet ar Severe liver disease Other causes of de Repeated dialysis ( Inherited hyperam SIADH (syndrome c Pregnancy. DECREASED RATIO (<1 Nhenacimide thera Rhabdomyolysis (r Muscular patients NAPPROPIATE RATIO Diabetic ketoacido should produce an in Cephalosporin ther STIMATED GLOMERL CKD STAGE G1	(e.g. ureter co ass (subnorma tetracycline, gl 0:1) WITH ELEV (BUN rises dis superimposed 0:1) WITH DEC osis. d starvation. creased urea s urea rather tha monemias (urea f inappropiate 0:1) WITH INCF oy (accelerates eleases muscle who develop re- sis (acetoaceta creased BUN/c apy (interferes LAR FILTERATIO	I creatinine production) ucocorticoids) (ATED CREATININE LEVELS proportionately more that on renal disease. REASED BUN : an creatinine diffuses our tea is virtually absent in bl antidiuretic harmone) du REASED CREATININE: to conversion of creatine t creatinine). enal failure. te causes false increase reatinine ratio). with creatinine measure DI SCRIPTION prmal kidney function	an creatinine t of extracelli ood). ue to tubular o creatinine) in creatinine ment). GFR ( mL/	ular fluid). secretion of urea. with certain metho <u>min/1.73m2 )</u>	odologies,resu ASSOCIATEE No prot	<b>FINDINGS</b> einuria	mal ratio	) when de	hydratic
<ol> <li>Reduced muscle m Certain drugs (e.g. NCREASED RATIO (&gt;2 Prerenal azotemia DECREASED RATIO (&lt;1 Acute tubular necr Low protein diet ar Severe liver disease Other causes of de Severe liver disease Other causes of de Repeated dialysis ( SIADH (syndrome c Pregnancy. DECREASED RATIO (&lt;1 Phenacimide thera Rhabdomyolysis (r Muscular patients NAPPROPIATE RATIO Liabetic ketoacido should produce an in Cephalosporin ther EXTIMATED GLOMERL CKD STAGE         </li> </ol>	(e.g. ureter co ass (subnorma tetracycline, gl 0:1) WITH ELEV (BUN rises dis superimposed 0:1) WITH DEC osis. d starvation. creased urea s urea rather tha monemias (ure f inappropiate 0:1) WITH INCF oy (accelerates eleases muscle who develop re sis (acetoaceta creased BUN/c apy (interferes LAR FILTERATIO	I creatinine production) ucocorticoids) <b>ATED CREATININE LEVELS</b> proportionately more that on renal disease. <b>REASED BUN :</b> ynthesis. an creatinine diffuses our tea is virtually absent in bl antidiuretic harmone) du <b>REASED CREATININE:</b> to conversion of creatine t creatinine). enal failure. te causes false increase i reatinine ratio). with creatinine measure <b>DESCRIPTION</b> fidney damage with	an creatinine t of extracelli ood). ue to tubular o creatinine) in creatinine ment). GFR ( mL/	ular fluid). secretion of urea. with certain metho min/1.73m2 )	odologies,resu ASSOCIATEL No prot Presence o	FINDINGS einuria f Protein ,		) when de	hydratic
A. Reduced muscle m Certain drugs (e.g. NCREASED RATIO (>2 Prerenal azotemia DECREASED RATIO (<1 Acute tubular necr Low protein diet ar Severe liver disease Other causes of de Repeated dialysis ( Inherited hyperam SIADH (syndrome c Pregnancy. DECREASED RATIO (<1 Nhenacimide thera Rhabdomyolysis (r Muscular patients NAPPROPIATE RATIO Diabetic ketoacido should produce an in Cephalosporin ther ESTIMATED GLOMERL CKD STAGE G1 G2	(e.g. ureter co ass (subnorma tetracycline, gl 0:1) WITH ELEV (BUN rises dis superimposed 0:1) WITH DEC osis. d starvation. creased urea s urea rather tha monemias (urea f inappropiate 0:1) WITH INCF oy (accelerates eleases muscle who develop re- sis (acetoaceta creased BUN/c apy (interferes LAR FILTERATIO	I creatinine production) ucocorticoids) (ATED CREATININE LEVELS proportionately more that on renal disease. REASED BUN : an creatinine diffuses our ta is virtually absent in bl antidiuretic harmone) du REASED CREATININE: to conversion of creatine t creatinine). enal failure. te causes false increase reatinine ratio). with creatinine measure DESCRIPTION mmal kidney function (idney damage with normal or high GFR	an creatinine t of extracelli ood). ue to tubular o creatinine) in creatinine ment). GFR ( mL/	ular fluid). secretion of urea. with certain metho <u>min/1.73m2 )</u> >90	odologies,resu ASSOCIATEE No prot	FINDINGS einuria f Protein ,		) when de	hydratic
A. Reduced muscle m Certain drugs (e.g. NCREASED RATIO (>2 Prerenal azotemia DECREASED RATIO (<1 Acute tubular necr Low protein diet ar Severe liver disease Other causes of de Repeated dialysis ( Inherited hyperam SIADH (syndrome c Regnancy. DECREASED RATIO (<1 Nuscular patients Nuscular patients Nuscular patients Nuscular patients Nuscular patients Nuscular patients Nuscular patients Nuscular patients CEphalosporin ther STIMATED GLOMERL G1 G2 G3a	(e.g. ureter co ass (subnorma tetracycline, gl 0:1) WITH ELEV (BUN rises dis superimposed 0:1) WITH DEC osis. d starvation. creased urea s urea rather tha monemias (urea f inappropiate 0:1) WITH INCF oy (accelerates eleases muscle who develop re- sis (acetoaceta creased BUN/c apy (interferes LAR FILTERATIO	I creatinine production) ucocorticoids) (ATED CREATININE LEVELS proportionately more that on renal disease. REASED BUN : an creatinine diffuses our ta is virtually absent in bl antidiuretic harmone) du REASED CREATININE: a conversion of creatine t creatinine). enal failure. te causes false increase reatinine ratio). with creatinine measure DI RATE: DESCRIPTION ormal kidney function (idney damage with normal or high GFR 111 111 111 111 111 111 111 1	an creatinine t of extracelli ood). ue to tubular o creatinine) in creatinine ment). GFR ( mL/	ular fluid). secretion of urea. with certain metho <u>min/1.73m2 )</u> >90 >90 0 -89	odologies,resu ASSOCIATEL No prot Presence o	FINDINGS einuria f Protein ,		) when de	hydratic
A. Reduced muscle m Certain drugs (e.g. NCREASED RATIO (>2 Prerenal azotemia DECREASED RATIO (<1 Acute tubular necr Low protein diet ar Severe liver disease Other causes of de Repeated dialysis ( Inherited hyperam SIADH (syndrome c Pregnancy. DECREASED RATIO (<1 Nhenacimide thera Rhabdomyolysis (r Muscular patients NAPPROPIATE RATIO Diabetic ketoacido should produce an in Cephalosporin ther ESTIMATED GLOMERL CKD STAGE G1 G2	(e.g. ureter co ass (subnorma tetracycline, gl 0:1) WITH ELEV (BUN rises dis superimposed 0:1) WITH DEC osis. d starvation. creased urea so urea rather tha monemias (urea f inappropiate 0:1) WITH INCF oy (accelerates eleases muscle who develop ro- sis (acetoaceta creased BUN/c apy (interferes LAR FILTERATIO No No No No	I creatinine production) ucocorticoids) (ATED CREATININE LEVELS proportionately more that on renal disease. REASED BUN : an creatinine diffuses our ta is virtually absent in bl antidiuretic harmone) du REASED CREATININE: to conversion of creatine t creatinine). enal failure. te causes false increase reatinine ratio). with creatinine measure DESCRIPTION mmal kidney function (idney damage with normal or high GFR	an creatinine t of extracelli ood). ue to tubular o creatinine) in creatinine ment). GFR ( mL/ 6 3	ular fluid). secretion of urea. with certain metho <u>min/1.73m2 )</u> >90	odologies,resu ASSOCIATEL No prot Presence o	FINDINGS einuria f Protein ,		) when de	hydratic





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST









	<b>Dr. Vinay Chopra</b> MD (Pathology & Microbio Chairman & Consultant Pa	ology) MI	m <b>Chopra</b> D (Pathology) ht Pathologist
NAME	: Mrs. RAJNI		
AGE/ GENDER	: 30 YRS/FEMALE	PATIENT ID	: 1687604
<b>COLLECTED BY</b>	:	<b>REG. NO./LAB NO.</b>	: 012412010037
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	<b>COLLECTION DATE</b>	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	<b>REPORTING DATE</b>	: 01/Dec/2024 02:45PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA	CANTT	
Test Name	Va	lue Unit	<b>Biological Reference interval</b>

COMMENTS:

Estimated Glomerular filtration rate (eGFR) is the sum of filtration rates in all functioning nephrons and so an estimation of the GFR provides a measure of functioning nephrons of the kidney.
 eGFR calculated using the 2009 CKD-EPI creatinine equation and GFR category reported as per KDIGO guideline 2012
 In patients, with eGFR creatinine between 45-59 ml/min/1.73 m2 (G3) and without any marker of Kidney damage, It is recommended to measure of CFD with the commended to measure

3. In patients, with eGFR cleaning between 45-59 minimit 1.73 m2 (G3) and without any marker of Kidney damage, it is recommended to measure eGFR with Cystatin C for confirmation of CKD
4. eGFR category G1 OR G2 does not fulfill the criteria for CKD, in the absence of evidence of Kidney Damage
5. In a suspected case of Acute Kidney Injury (AKI), measurement of eGFR should be done after 48-96 hours of any Intervention or procedure
6. eGFR calculated by Serum Creatinine may be less accurate due to certain factors like Race, Muscle Mass, Diet, Certain Drugs. In such cases, eGFR should be calculated using Serum Cystatin C
7. A decrease in eGFR implies either progressive renal disease, or a reversible process causing decreased nephron function (eg, severe dehydration).

ADVICE:

KDIGO guideline, 2012 recommends Chronic Kidney Disease (CKD) should be classified based on cause, eGFR category and Albuminuria (ACR) category. GFR & ACR category combined together reflect risk of progression and helps Clinician to identify the individual who are progressing at more rapid rate than anticipated





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com







	1	<b>Dr. Vinay Chopra</b> MD (Pathology & Microbic Chairman & Consultant Pa			m Chopra D (Pathology) nt Pathologist	
NAME	: Mrs. RAJNI					
AGE/ GENDER	: 30 YRS/FEM	ALE	PATIE	NT ID	: 1687604	
COLLECTED BY	:		REG. N	O./LAB NO.	: 012412010037	
REFERRED BY	:		REGIS	<b>FRATION DATE</b>	: 01/Dec/2024 12:37 PM	
BARCODE NO.	:01521805		COLLI	CTION DATE	:01/Dec/2024 12:48PM	
CLIENT CODE.	: KOS DIAGNO	STIC LAB	REPO	RTING DATE	:01/Dec/2024 02:04PM	
CLIENT ADDRESS	: 6349/1, NIC	HOLSON ROAD, AMBALA	CANTT			
Test Name		Va	lue	Unit	Biological Refer	rence interval
		EN	DOCRINO	LOGY		
		THYROID	FUNCTION	TEST: TOTAI		
TRIIODOTHYRONI		۸ 0. RTICLE IMMUNOASSAY)	786	ng/mL	0.35 - 1.93	
THYROXINE (T4): S		7. RTICLE IMMUNOASSAY)	09	µgm/d	L 4.87 - 12.60	
THYROID STIMULA		IE (TSH): SERUM 1.3 RTICLE IMMUNOASSAY)	357	µIU/m	L 0.35 - 5.50	
3rd GENERATION, ULT		THOLE ININIONOASSAT)				
INTERPRETATION:						
day has influence on the	<i>measured serum TSI</i> lure at any level of	<i>I concentrations</i> . TSH stimulation of the hypothalamic	es the production	and secretion of the	Dpm. The variation is of the order of 50 metabolically active hormones, thyro ther underproduction (hypothyroidism	oxine (T4)and
CLINICAL CONDITION		T3	T4		TSH	
Primary Hypothyroidis	m:	Reduced	Redu	ced	Increased (Significantly)	
Subclinical Hypothyroi	dism:	Normal or Low Normal	Normal	r Low Normal	High	

111	ЛІТД	TIC	)NS:	-

Primary Hyperthyroidism:

Subclinical Hyperthyroidism:

1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG), and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests.

Increased

Normal or High Normal

Reduced (at times undetectable)

Reduced

2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs (e.g.: phenytoin , salicylates).

3. Serum T4 levels in neonates and infants are higher than values in the normal adult , due to the increased concentration of TBG in neonate serum.

4. TSH may be normal in central hypothyroidism , recent rapid correction of hyperthyroidism or hypothyroidism , pregnancy , phenytoin therapy.

TRIIODOTHYRONINE (T3)		THYROXINE (T4)		THYROID STIMULATING HORMONE (TSH)		
Age	Refferance Range (ng/mL)	Age	Refferance Range (µg/dL)	Age	Reference Range ( μIU/mL)	
0 - 7 Days	0.20 - 2.65	0 - 7 Days	5.90 - 18.58	0 - 7 Days	2.43 - 24.3	
7 Days - 3 Months	0.36 - 2.59	7 Days - 3 Months	6.39 - 17.66	7 Days - 3 Months	0.58 - 11.00	
3 - 6 Months	0.51 - 2.52	3 - 6 Months	6.75 - 17.04	3 Days – 6 Months	0.70 - 8.40	
6 - 12 Months	0.74 - 2.40	6 - 12 Months	7.10 - 16.16	6 – 12 Months	0.70 - 7.00	

Increased

Normal or High Normal






DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)









	<b>Dr. Vinay Chopra</b> MD (Pathology & Microbiology) Chairman & Consultant Patholo		(Pathology)
NAME	: Mrs. RAJNI		
AGE/ GENDER	: 30 YRS/FEMALE	PATIENT ID	: 1687604
COLLECTED BY	:	REG. NO./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	<b>COLLECTION DATE</b>	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	<b>REPORTING DATE</b>	: 01/Dec/2024 02:04PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CAN	ГТ	

Test Name			Value	Uni	t	<b>Biological Reference interval</b>
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50	
11- 19 Years	0.35 - 1.93	11 - 19 Years	4.87-13.20	11 – 19 Years	0.50 - 5.50	
> 20 years (Adults)	0.35 - 1.93	> 20 Years (Adults)	4.87 - 12.60	> 20 Years (Adults)	0.35-5.50	
	RECO	MMENDATIONS OF TSH	LEVELS DURING PRE	GNANCY ( µIU/mL)		
	1st Trimester			0.10 - 2.50		
	2nd Trimester			0.20 - 3.00		
	3rd Trimester			0.30 - 4.10		

### **INCREASED TSH LEVELS:**

1.Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.

2. Hypothyroid patients receiving insufficient thyroid replacement therapy.

3. Hashimotos thyroiditis

4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.

5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

**DECREASED TSH LEVELS:** 

1.Toxic multi-nodular goiter & Thyroiditis.

2. Over replacement of thyroid hormone in treatment of hypothyroidism.

3. Autonomously functioning Thyroid adenoma

4. Secondary pituitary or hypothalamic hypothyroidism

5. Acute psychiatric illness

6.Severe dehydration.

7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.

8. Pregnancy: 1st and 2nd Trimester





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com







		Chopra y & Microbiology) Consultant Pathologist	Dr. Yugan MD CEO & Consultant	(Pathology)	
NAME	: Mrs. RAJNI				
AGE/ GENDER	: 30 YRS/FEMALE	PATIE	ENT ID	: 1687604	
COLLECTED BY	:	REG. N	NO./LAB NO.	: 012412010037	
REFERRED BY	:	REGIS	TRATION DATE	: 01/Dec/2024 12:37 PM	
BARCODE NO.	: 01521805	COLLE	ECTION DATE	:01/Dec/2024 12:48PM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPO	RTING DATE	:01/Dec/2024 02:04PM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROA	D, AMBALA CANTT			
Test Name		Value	Unit	Biological Refer	ence interval
2.The major chemica 3.Physiological funct	d by the anterior pituitary gla il controlling prolactin secretii ion of prolactin is the stimula	on is dopamine, which inhi Ition of milk production. In	bits prolactin secre normal individuals	tion from the pituitary. , the prolactin level rises in reg postpartum period, and also i	sponse to
newborn infant.	uch as sleep, exercise, hipple s	stimulation, sexual intercol	urse, nypogiycemia,	postpartum period, and also i	is elevated in the
INCREASED (HYPERPE 1. Prolactin-secreting	ROLACTEMIA): pituitary adenoma (prolactine	oma, which is 5 times more	frequent in female	s than males).	
2.Functional and org	anic disease of the hypothala	mus.	in equeent in remain		
3.Primary hypothyro 4.Section compressic	on of the pituitary stalk.				
5.Chest wall lesions 6.Ectopic tumors.	and renal failure.				
7.DRUGS:- Anti-Dopa receptors, or serotor ,Opiates, High doses	minergic drugs like antipsycho nin reuptake (anti-depressants of estrogen or progesterone,	s of all classes, ergot deriva	itives, some illegal o	that affect CNS serotonin meta drugs such as cannabis), Antihy us medications (Isoniazid).	abolism, seroton pertensive drug
2.Loss of libido, impo from decreased mus	lactorrhea, oligomHyperprola otence, infertility, and hypogo cle mass and osteoporosis. levels >13 ng/mL are indicative	nadism in males. Postmenc	rhea or amenorrhe opausal and premer	a, and infertility in premenopa lopausal women, as well as me	ausal females. en, can also suffe

adenoma is present, 5. Whereas levels >250 ng/mL are usually associated with a prolactin-secreting tumor.

#### CAUTION:

Prolactin values that exceed the reference values may be due to macroprolactin (prolactin bound to immunoglobulin). Macroprolactin should be evaluated if signs and symptoms of hyperprolactinemia are absent, or pituitary imaging studies are not informative.





**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT

3. In males, prolactin levels >13 ng/mL are indicative of hyperprolactinemia.
4. In women, prolactin levels >27 ng/mL in the absence of pregnancy and postpartum lactation are indicative of hyperprolactinemia.
5. Clear symptoms and signs of hyperprolactinemia are often absent in patients with serum prolactin levels <100 ng/mL.</li>
4. Mild to moderately increased levels of serum prolactin are not a reliable guide for determining whether a prolactin-producing pituitary addressed levels of 250 ng/mL are not a reliable guide for determining whether a prolactin-producing pituitary.





	MD (F	<b>/inay Chopra</b> /athology & Microbiology) nan & Consultant Patholog		(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE		PATIENT ID	: 1687604
COLLECTED BY	:		REG. NO./LAB NO.	: 012412010037
REFERRED BY	:		<b>REGISTRATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	:01521805		COLLECTION DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC	LAB	<b>REPORTING DATE</b>	:01/Dec/202403:28PM
CLIENT ADDRESS	: 6349/1, NICHOLS	ON ROAD, AMBALA CANT	Г	
		Value	Unit	<b>Biological Reference interval</b>
Test Name				
Test Name		ANTI MULLERIAN	HORMONE (AMH) GE	N II
ANTI MULLERIAN	HORMONE (AMH) G Hemiluminescence imm	EN II: SERUM 3.31	<b>HORMONE (AMH) GE</b> ng/mL	<b>N II</b> 0.05 - 11.00
ANTI MULLERIAN by ECLIA (ELECTROCH INTERPRETATION:-		EN II: SERUM 3.31 JUNOASSAY)		

OVARIAN FERTILITY POTENTIAL	AMH VALUES IN (ng/mL)
OPTIMAL FERTILITY:	4.00 – 6.80 ng/mL
SATISFACTORY FERTILITY:	2.20 – 4.00 ng/mL
LOW FERTILITY:	0.30 – 2.20 ng/mL
VERY LOW/UNDETECTABLE:	0.00 – 0.30 ng/mL
HIGH LEVEL:	>6.8 ng/mL (PCOD/GRANULOSA CELL TUMOUR)

Anti Mullerian Hormone (AMH) is also known as Mullerian Inhibiting Substance provided by sertoli cells of the testis in males and by ovarian granulose cells in females up to antral stage in females.

## IN MALES:

1.It is used to evaluate testicular presence and function in infants with intersex conditions or ambiguous genitalia, and to distinguish between cryptorchidism and anorchia in males

## IN FEMALES:


1. During reproductive age, follicular AMH productionbegins during the primary stage, peaks in preantral stage & has influence on follicular sensitivity to FSH which is impoetant in selection for follicular dominance. AMH levels thus represents the pool or number of primordial follicles but not thequality of oocytes. AMH does not vary significantly during menstrual cycle & hence can be measured independently of day of cycle. 2. Polycystic ovarian syndrome can elevate AMH 2 to 5 fold higher than age specific reference range & predict anovulatory, irregular cycles, ovarian tumours like Granulosa cell tumour are often associated with higher AMH levels.

3.Obese women are often associated with diminished ovarian reserve and can have 65% lower mean AMH levels than non-obese women. 4.In females , AMH levels do not change significantly throughout the menstrual cycle and decrease with age.

5. Assess Ovarian Reserve - correlates with the number of antral follicies in the ovaries.

6.Evaluate fertility potential and ovarian response in IVF- Women with low AMG levels are more likely to the poor ovarian responders. 7.Assess the condition of Polycystic Ovary and premature ovarian failure.

A combination of Age, Ultrasound markers-Ovarian Volume and Antral Follicle Count, AMH and FSH levels are useful for optimal assessment of ovarian reserve. Studies in various fertility clinics are ongoing to establish optimal AMH concentretaion for predicting response to invitro fertilization, however, given below is suggested interpretative reference.



 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt - 133 001, Haryana

 KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT





EXCELLENCE IN HEALTHCARE & DIAGNOSTICS Dr. Yugam Chopra

MD (Pathology)

	Chairman & Consultant Pathologi	st CEO & Consultant	Pathologist
NAME	: Mrs. RAJNI		
AGE/ GENDER	: 30 YRS/FEMALE	PATIENT ID	: 1687604
<b>COLLECTED BY</b>	:	REG. NO./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	<b>COLLECTION DATE</b>	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	:01/Dec/2024 03:28PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT	ſ	

Dr. Vinay Chopra MD (Pathology & Microbiology)

Test Name		Value	Unit	<b>Biological Reference interval</b>
	Categorization for fertility based on AMH for age group (20 to 45 yrs)	Follicle counts	(day 3)	to IVF/COH cycle
Below 0.3	Very low	Below 4	Above 20	Negligible/Poor
0.3 to 2.19	Low	4 - 10	Usually 16 - 20	Reduced
2.19 t0 4.00	Satisfactory	11 - 25	Within reference range or between 11 - 15	Safe/Normal
Above 4.00	Optimal	Upto 30 and Above	Within reference range or between 11 – 15 or Above 15	Possibly Excessive

# INCREASED:

1.Polycystic ovarian syndrome (most common)

2. Ovarian Tumour: Granulosa cell tumour

# DECREASED:

1. Anorchia, Abnormal or absence of testis in males

2.Pseudohermaphroditism

3.Post Menopause

## NOTE:

1.AMH measurement alone is seldom suffcient for diagnosis and results should be interpreted in the light of clinical finding and other relevant test such as ovarian ultrasonography(In fertility applications); abdominal or testicular ultrasound(intersex or testicular function applications); measurement of sex steroids (estradiol,Progesterone,Testosterone),FSH, Inhibin B (For fertility), and Inhibin A and B (for tumour work up). 2.Conversion of AMH grom ng/mL to pmol/L can be performed by using equation 1 ng/mL = 7.14 pmol/L





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com







	Dr. Vinay Cl MD (Pathology Chairman & Co			(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE		PATIENT ID	: 1687604
COLLECTED BY	:		REG. NO./LAB NO.	: 012412010037
REFERRED BY	:		<b>REGISTRATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805		COLLECTION DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		<b>REPORTING DATE</b>	:01/Dec/2024 02:04PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD	, AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
			OLOGY/SEROLOGY	
	HEPAT	ITIS C VIRUS (	HCV) ANTIBODY: TO	DTAL
	HEPATI BODY (HCV) TOTAL: SERUM NESCENT MICROPARTICLE IMMUNO	0.09	<b>HCV) ANTIBODY: TC</b> S/CO	DTAL NEGATIVE: < 1.00 POSITIVE: > 1.00
by CMIA (CHEMILUMIN HEPATITIS C ANTI RESULT by CMIA (CHEMILUMIN	BODY (HCV) TOTAL: SERUM	0.09 ASSAY) NON - RE	S/CO	NEGATIVE: < 1.00
by CMIA (CHEMILUMIN HEPATITIS C ANTI RESULT by CMIA (CHEMILUMIN INTERPRETATION:-	BODY (HCV) TOTAL: SERUM NESCENT MICROPARTICLE IMMUNO/ BODY (HCV) TOTAL NESCENT MICROPARTICLE IMMUNO/	0.09 ASSAY) NON - RE	S/CO	NEGATIVE: < 1.00
by CMIA (CHEMILUMIN HEPATITIS C ANTI RESULT by CMIA (CHEMILUMIN INTERPRETATION:-	BODY (HCV) TOTAL: SERUM NESCENT MICROPARTICLE IMMUNOA BODY (HCV) TOTAL	0.09 ASSAY) NON - RE	S/CO	NEGATIVE: < 1.00 POSITIVE: > 1.00
by CMIA (CHEMILUMIN HEPATITIS C ANTI RESULT by CMIA (CHEMILUMIN INTERPRETATION:- R	BODY (HCV) TOTAL: SERUM NESCENT MICROPARTICLE IMMUNO/ BODY (HCV) TOTAL NESCENT MICROPARTICLE IMMUNO/ ESULT (INDEX) < 1.00 > =1.00	ASSAY) ASSAY) ASSAY) REACTIVE/AS	S/CO CACTIVE REMARKS NON - REACTIVE/NOT - DE SYMPTOMATIC/INFECTIVE ST	NEGATIVE: < 1.00 POSITIVE: > 1.00

1. Indicator of past or present infection, but does not differentiate between Acute/ Chronic/Resolved Infection. 2. Routine screening of low and high prevelance population including blood donors.

NOTE:

1. False positive results are seen in Auto-immune disease, Rheumatoid Factor, HYpergammaglobulinemia, Paraproteinemia, Passive antibody transfer, Anti-idiotypes and Anti-superoxide dismutase.

2. False negative results are seen in early Acute infection, Immunosuppression and Immuno-incompetence.

3. HCV-RNA PCR recommended in all reactive results to differentiate between past and present infection.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	Dr. Vinay Ch MD (Pathology & Chairman & Con		Dr. Yugan MD CEO & Consultant	(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE	PAT	IENT ID	: 1687604
COLLECTED BY	:	REG	NO./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:	REG	ISTRATION DATE	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	COL	LECTION DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REP	ORTING DATE	:01/Dec/2024 02:04PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interva
ANTI HUI HIV 1/2 AND P24 /		<b>CY VIRUS (HIV) D</b> 0.08		Biological Reference interval H (P-24 ANTIGEN DETECTION) NEGATIVE: < 1.00 POSITIVE: > 1.00
ANTI HUI HIV 1/2 AND P24 A by CMIA (CHEMILUMIN HIV 1/2 AND P24 A	ANTIGEN: SERUM	CY VIRUS (HIV) D 0.08 SSAY) NON - REACTI	U <b>O ULTRA WITH</b> S/CO	I (P-24 ANTIGEN DETECTION) NEGATIVE: < 1.00
ANTI HUI HIV 1/2 AND P24 <i>I</i> by CMIA (CHEMILUMIN HIV 1/2 AND P24 <i>I</i> by CMIA (CHEMILUMIN INTERPRETATION:-	ANTIGEN: SERUM iescent microparticle immunoa. ANTIGEN RESULT	CY VIRUS (HIV) D 0.08 SSAY) NON - REACTI	U <b>O ULTRA WITH</b> S/CO	I (P-24 ANTIGEN DETECTION) NEGATIVE: < 1.00
ANTI HUI HIV 1/2 AND P24 <i>J</i> by CMIA (CHEMILUMIN HIV 1/2 AND P24 <i>J</i> by CMIA (CHEMILUMIN <u>INTERPRETATION:-</u> RESUI < 1	ANTIGEN: SERUM IESCENT MICROPARTICLE IMMUNOA ANTIGEN RESULT IESCENT MICROPARTICLE IMMUNOA	CY VIRUS (HIV) D 0.08 SSAY) NON - REACTI	U <b>O ULTRA WITH</b> S/CO VE	H (P-24 ANTIGEN DETECTION) NEGATIVE: < 1.00 POSITIVE: > 1.00

exposed to HIV 1/2 infection or the sample has been tested during the "window phase" i.e. before the development of detectable levels of antibodies. Hence a Non Reactive result does not exclude the possibility of exposure or infection with HIV 1/2. **RECOMMENDATIONS:** 1. Results to be clinically correlated

2. Rarely falsenegativity/positivity may occur.





**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





	Dr. Vinay Ch MD (Pathology & Chairman & Con	Microbiology)	Dr. Yugam MD & Consultant	(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE	PATIENT ID	1	: 1687604
COLLECTED BY	:	REG. NO./LA	B NO.	: 012412010037
REFERRED BY	:	REGISTRAT	ION DATE	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	COLLECTIO	N DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING	DATE	:01/Dec/2024 02:04PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
	HEPATITI	S B SURFACE ANTIGEN	(HBsAg) U	JLTRA
SERUM	FACE ANTIGEN (HBsAg):	0.3 SSAY)	S/CO	NEGATIVE: < 1.0 POSITIVE: > 1.0
by CMIA (CHEMILUMI	ACE ANTELCEN (IID - A -)	NON REACTIVE		
HEPATITIS B SURI RESULT				
HEPATITIS B SURI RESULT by CMIA (CHEMILUMII	ACE AN HIGEN (HBSAg)			
HEPATITIS B SURI RESULT by CMIA (CHEMILUMII INTERPRETATION: RESU	NESCENT MICROPARTICLE IMMUNOA	SSAY)	MARKS	
HEPATITIS B SURI RESULT by CMIA (CHEMILUMII INTERPRETATION: RESUI	NESCENT MICROPARTICLE IMMUNOA	SSAY)	MARKS GATIVE (-ve) SITIVE (+ve)	

Hepatitis B Virus (HBV) is a member of the Hepadna virus family causing infection of the liver with extremely variable clinical features. Hepatitis B is transmitted primarily by body fluids especially serum and also spread effectively sexually and from mother to baby. In most individuals HBV hepatitis is self limiting, but 1-2 % normal adolescent and adults develop Chronic Hepatitis. Frequency of chronic HBV infection is 5-10% in immunocompromised patients and 80 % neonates. The initial serological marker of acute infection is HBsAg which typically appears 2-3 months after infection and disappears 12-20 weeks after onset of symtoms. Persistence of HBsAg for more than 6 months indicates carrier state or Chronic Liver disease.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com
 www.koshealthcare.com



Page 24 of 26





		h <b>opra</b> & Microbiology) nsultant Pathologist	Dr. Yugam MD CEO & Consultant	(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE	PATI	ENT ID	: 1687604
COLLECTED BY	:	REG.	NO./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:	REGI	STRATION DATE	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805	COLL	ECTION DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPO	RTING DATE	: 02/Dec/2024 07:16AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD	, AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
	RUBELLA	ANTIBODIES EVAI	LUATION IgG AN	ND IgM
RUBELLA ANTIBOI by CLIA (CHEMILUMINI	DIES IgM escence immunoassay)	0.475	IU/mL	NEGATIVE: < 2.0 EQUIVOCAL: 2.0 - 3.0 POSITIVE: > 3.0
RUBELLA ANTIBOI by CLIA (CHEMILUMINI INTERPRETATION:	DIES IgG escence immunoassay)	9.586 <sup>H</sup>	IU/mL	NEGATIVE: < 2.0 POSITIVE: > 2.0

**KOS Diagnostic Lab** (A Unit of KOS Healthcare)

Rubella virus, the only member of rubivirus genus, causes rubella (also known as german measles), an acute exanthematous infection of children and adults. The clinical illnss is characterized by rash, fever and lymphadenopathy and can resemble a mild case of measles. The virus also cause arthralgias and occasional encephalitis. Infection is particularly disastrous if contracted during the first 4 months of pregnancy. If not immunologically protected, women infected during pregnancy run a high risk of embryo-foetal damage. Congenital Rubella causes a wide range of severe defects in foetus, including cataract, deafness, hepatosplenomegaly, psychomotor retardation, bone alterations, cardiopathies, neuropathics and diabate. neuropathies and diabetes.

TEST UTILITY:

1. IgM antibodies become detectable in a few days after the onset of signs and symptoms and reach peak level in 7 - 10 days. These antibodies persist, but rapidly diminishes in concentration over the next 4 - 5 weeks until the antibody is no longer clinically detectable. While the presence of IgM antibodies suggests current or recent infection, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection or immunization. The presence of IgM antibodies in a new born indicates that the bay was infected during pregnancy because the mother IgM antibodies do not pass to the baby through umbilical cord.

2. Rubella IgG antibody can be formed following rubella infection or after rubella vaccination. A reactive result is consistent with immune status to rubella virus. The presence of IgG antibodies, but not IgM antibodies, in a newborn means that the mothers IgG antibodies have passed to the baby in utero and these antibodies may protect the infant from rubella infection during the initial six months of life. LIMÍTATIONS:

1. Rubella IgM test results are intended as an aid to the diagnose of active or recent infection. They should however, be interpreted in conjugation with other clinical findings and diagnostic procedures

2. The antibody titre of a single serum specimen cannot be used to determine recent infection. Specimens obtained too early, or too late, during

2. The antibody thre of a single serum specimen cannot be used to determine recent infection. Specimens obtained too early, or too fate, during the course of infection, may not demonstrate detectable levels of IgM antibody. Samples collected too early may not have detectable levels of IgG. Paired samples (acute & convalescent) should be collected and tested concurrently to demonstrate seroconversation. 3. A positive Rubella IgM result may not always indicate a primary acute infection, as IgM has a tendency to persist, even at high levels, after primay infection. *FALSE POSITIVE RESULTS MAY ALSO OCCUR DUE TO RHEUMATOID FACTOR AND ANTI-NUCLEUR ANTIBODIES*. Hence, IgG avidity testing is recommended to differentiate between primay infection, IgM persistence and reactivation. IgG antibody results should be interpreted in conjugation with clinical evaluation and the and the results of other diagnostic procedures.





**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



TEST PERFORMED AT KOS DIAGNOSTIC LAB. AMBALA CANTT





		y & Microbiology)	Dr. Yugan MD CEO & Consultant	(Pathology)
NAME	: Mrs. RAJNI			
AGE/ GENDER	: 30 YRS/FEMALE	PATIEN	IT ID	: 1687604
COLLECTED BY	:	REG. NO	D./LAB NO.	: 012412010037
<b>REFERRED BY</b>	:		<b>RATION DATE</b>	: 01/Dec/2024 12:37 PM
BARCODE NO.	: 01521805		TION DATE	:01/Dec/2024 12:48PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		TING DATE	: 01/Dec/2024 01:23PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROA	AD, AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
2. High titer (>1:16) - 3.Low titer (<1:8) - bi 4. Treatment of prima 5. Rising titer (4X) ind 6. May benonreactive 7. Reactive and weak	positive until 7 - 10 days after active disease. fological falsepositive test in 9 ary syphillis causes progressiv icates relapse,reinfection, or e in early primary, late latent,	0% cases or due to late or late re decline tonegative VDRL wi treatment failure and need fo and late syphillis (approx. 25 s be confirmedwith FTA-ABS (f	ithin 2 years. Ir retreatment. 5% ofcases). Fluorescent trepone	NON REACTIVE
1.Acute viral illnesse	s (e.g., hepatitis, measles, inf hlamydia; Malaria infection.			
1.Serious underlying 2.Intravenous drug u 3.Rheumatoid arthrit 4.<10 % of patients of	SITIVE TEST RESULTS (>6 MON disease e.g., collagen vascula sers. tis, thyroiditis, AIDS, Sjogren's Ider thanage 70 years. he anti-hypertensive drugs.	ar diseases, leprosy ,malignal		
		*** End Of Report *	* * *	

\*\*\* End Of Report \*\*\*





**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



# Patient report

Bio-Rad	DATE: 12/02/2024
D-10	TIME: 05:45 AM
S/N: #DJ6F040603	Software version: 4.30-2
Sample ID:	01521805
Injection date	12/02/2024 03:43 AM
Injection #: 29	Method: HbA2/F
Rack #:	Rack position: 10



Peak table - ID: 01521805						
Peak	R.time	Height	Area	Area %		
Unknown	0.14	2511	5154	0.3		
Ala	0.20	3189	12253	0.8		
Alb	0.29	4059	14705	0.9		
F	0.48	1175	9267	< 0.8 *		
LA1c/CHb-1	0.75	1563	8350	0.5		
LA1c/CHb-2	0.80	1433	10300	0.7		
Alc	0.98	5151	55110	5.0		
P3	1.54	10293	75991	4.9		
A0	1.74	306586	1319891	84.5		
A2	3.30	3347	50867	3.6		
Total Area:	1561888					

Concentration:	%
F	< 0.8 *
A1c	5.0
A2	3.6